Navigation Links
PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumors
Date:7/5/2011

A non-invasive PET imaging technique may identify lung cancers that respond best to tyrosine kinase inhibitors (TKIs), allowing doctors to better select patients for personalized therapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

"As more and more therapeutic agents are becoming available for non-small cell lung cancer therapy, selecting the best drug for each individual patient becomes increasingly challenging," said principal investigator Dr. Idris Bahce, of VU University Medical Center in Amsterdam, the Netherlands. "Predictive markers may offer guidance in personalizing therapy."

One marker that predicts tumor response to TKIs is the activating mutation of the epidermal growth factor receptor (EGFR) gene of the tumor cells, Dr. Bahce said. But it's not easy to obtain adequate tumor tissue from the patient for DNA analysis to determine whether the mutation exists.

In the study, non-small cell lung cancer (NSCLC) patients underwent PET (positron emission tomography) scans using radiolabeled erlotinib, a TKI.

"We found that patients who had an activating EGFR mutation also had an increased tracer uptake and were more sensitive to treatment with erlotinib as compared to those who did not have this mutation," Dr. Bahce said. "This is an important finding, as it indicates that this new imaging PET technique may be a non-invasive predictive marker that identifies NSCLC patients who benefit from treatment with TKIs."

Ten NSCLC patients, five with wild-type EGFR and five with activating EGFR mutations -- determined by DNA sequencing on tumor tissue -- were included in the study. Each was scanned twice using a procedure that included a low-dose computed tomography (CT) scan, a 10 minute [15O]water dynamic PET scan and a one-hour [11C]erlotinib dynamic PET scan.

Tumor uptake of [11C]erlotinib was significantly higher in the mutated group (median uptake (VT) = 1.70; range 1.33-2.30) than in the wild-type group (median uptake (VT) = 1.18; range, 0.75-1.34; p = 0.03). This difference was not due to differences in tumor perfusion. Tracer [11C]erlotinib uptake correlated with tumor response to subsequent erlotinib treatment, as only high-uptake tumors responded to treatment.


'/>"/>

Contact: Renee McGaw
renee.mcgaw@ucdenver.edu
31-205-493-413
International Association for the Study of Lung Cancer
Source:Eurekalert

Related medicine news :

1. New Website Provides Counselors with Instant Help for Troubled Kids
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
4. Providence Service Corporation Relocates Corporate Headquarters to Downtown Tucson
5. Keenan Chief Strategy Officer Selected to Join Editorial Board of Payers & Providers
6. DavisPTnetwork Partners with the New York Physical Therapy Association to Provide Online Continuing Education
7. Rhode Island Settlement Reflects Homeowner Liability for Serving Alcohol to Those Under 21, Says Providence Lawyer Mark Gemma
8. Southridge LLC Provides Equity Capital Through Private Agreement with PuraMed Bioscience
9. MarquisNet Co-Location Agreement with MessageBroadcast Helps Message Delivery Provider Expand World-Class Network
10. Top Raleigh Dentist Robert Williamson Designated A Preferred Invisalign Provider
11. Save the Children Provides Songs with Lifesaving Health and Nutrition Advice to Haitian Radio Stations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Healthcare Associates of McKinney announced today ... building at 8080 State Highway 121, Suite 210, McKinney, Texas 75070. It is ... 121. , As the practice has grown, the need for more space has been ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State ... convening academic faculty engaged in or interested in palliative care education and research. The ... be held in North County San Diego on Sept. 28 and 29, 2017, on ...
(Date:2/24/2017)... ... ... Fiber Network (IFN) President and CEO Kelly C. Dyer recently announced that he will ... the Management Committee when IFN was originally formed in 2002 where he was ultimately ... of the business plan. He became the first paid employee of IFN in ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... qualifying into the Senior International Elite division on February 12th. Ms. Esparza ... divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida is ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February 22, 2017 the ... to withdraw previous guidance issued by the Obama Administration requiring schools to ... May 2016 by the Obama Administration came in response to a growing number ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Research and Markets has announced the addition of the "Dry eye ... ... eye Drugs Price Analysis and Strategies - 2016, provides drug pricing data ... the following questions: What are the key ... positioned in the Global Dry eye market? What are ...
(Date:2/24/2017)... , Feb. 24, 2017 Medical ... ways to increase their self-service capabilities to manage ... Providers (HCPs). New research from consulting ... organizations have developed self-service website portals where HCPs ... is just one of many findings to emerge ...
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the ... provides separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin ... forecasts are provided for the period 2015 through 2022. Also, ... data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology: